Metastin/AXOR12 signaling not only suppressed the aggressive tumor phenotype in epithelial ovarian cancer (Hata et al. 2009), melanoma (Shirasaki et al. 2001), thyroid cancer (Ringel et al. 2002), esophageal carcinoma (Sanchez-Carbayo et al. 2003), urinary bladder cancer (Dhar et al. 2004), and gastric carcinoma (Ikeguchi et al. 2004), but also enhanced the expression of RCAN1 (Stathatos et al. 2005). Here, RCAN1 is linked to thyroid gland carcinoma.